GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sana Biotechnology Inc (NAS:SANA) » Definitions » EV-to-EBIT

Sana Biotechnology (Sana Biotechnology) EV-to-EBIT : -4.60 (As of May. 13, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sana Biotechnology EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sana Biotechnology's Enterprise Value is $1,469.57 Mil. Sana Biotechnology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-319.81 Mil. Therefore, Sana Biotechnology's EV-to-EBIT for today is -4.60.

The historical rank and industry rank for Sana Biotechnology's EV-to-EBIT or its related term are showing as below:

SANA' s EV-to-EBIT Range Over the Past 10 Years
Min: -23.51   Med: 0   Max: 0
Current: -4.6

SANA's EV-to-EBIT is ranked worse than
100% of 436 companies
in the Biotechnology industry
Industry Median: 9.28 vs SANA: -4.60

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Sana Biotechnology's Enterprise Value for the quarter that ended in Mar. 2024 was $2,007.87 Mil. Sana Biotechnology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-319.81 Mil. Sana Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -15.93%.


Sana Biotechnology EV-to-EBIT Historical Data

The historical data trend for Sana Biotechnology's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sana Biotechnology EV-to-EBIT Chart

Sana Biotechnology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial - - -6.79 -1.61 -2.41

Sana Biotechnology Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.20 -2.61 -2.08 -2.41 -6.28

Competitive Comparison of Sana Biotechnology's EV-to-EBIT

For the Biotechnology subindustry, Sana Biotechnology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sana Biotechnology's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sana Biotechnology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sana Biotechnology's EV-to-EBIT falls into.



Sana Biotechnology EV-to-EBIT Calculation

Sana Biotechnology's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1469.569/-319.813
=-4.60

Sana Biotechnology's current Enterprise Value is $1,469.57 Mil.
Sana Biotechnology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-319.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sana Biotechnology  (NAS:SANA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Sana Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-319.813/2007.867
=-15.93 %

Sana Biotechnology's Enterprise Value for the quarter that ended in Mar. 2024 was $2,007.87 Mil.
Sana Biotechnology's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-319.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sana Biotechnology EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Sana Biotechnology's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Sana Biotechnology (Sana Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
188 East Blaine Street, Suite 400, Seattle, WA, USA, 98102
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. Its operations include identifying and developing potential product candidates, executing preclinical studies, establishing manufacturing capabilities, acquiring technology, organizing and staffing the Company, business planning, establishing the company's intellectual property portfolio, raising capital, and providing general and administrative support for these operations.
Executives
Christian Hordo officer: SVP, Chief Business Officer C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE WA 98102
Flagship Ventures Fund V, L.p. 10 percent owner ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Douglas E Williams officer: EVP & President, R&D C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Bernard J Cassidy officer: EVP & General Counsel C/O TUMBLEWEED COMMUNICATIONS CORP, 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Patrick Y Yang director C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990
James J. Macdonald officer: See Remarks C/O SANA BIOTECHNOLOGY, INC., 188 EAST BLAINE STREET, SUITE 400, SEATTLE WA 98102
Sunil Agarwal officer: See Remarks 60 LEVERONI COURT, NOVATO CA 94949
Arch Venture Partners Ix, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Flagship Venturelabs V Manager Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship V Venturelabs Rx Fund, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Venturelabs V Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Arch Venture Fund Ix, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Ix Overage, L.p. 10 percent owner 8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Arch Venture Partners Ix Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631

Sana Biotechnology (Sana Biotechnology) Headlines

From GuruFocus

Sana Biotechnology to Host Research & Development Day

By sperokesalga sperokesalga 04-24-2023

Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-03-2023